Drug Trial Radar · NCT02475629
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
Last checked: Nov 20, 2026Latest source record: Mar 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 2015
Primary completion
Oct 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
Conditions
- HIV
Interventions
ibalizumabBiological
2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
Optimized Background Regimen (OBR)Drug
All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEFTime frame: Day 14
- Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol CorrectTime frame: Day 14
Locations
30 sites in 3 countries. Site status is shown where the registry gives one.
Long Beach Education and Research Consultants
Long Beach, California
W King Health Care Group
Los Angeles, California
Southern California Permanente Medical Group
Los Angeles, California
Ruane Medical and Clinical Research Institute
Los Angeles, California
Charles R. Drew Univ. of Med. & Science Clinical and Translational Research Center
Los Angeles, California
Anthony Mills, MD, Inc.
Los Angeles, California
AIDS Healthcare Foundation
Los Angeles, California
Palmtree Clinical Research Inc.
Palm Springs, California
Quest Clinical Research
San Francisco, California
Kaiser Foundation Research Institute
San Francisco, California
Yale University
New Haven, Connecticut
Circle Care Center, LLC
Norwalk, Connecticut
Georgetown University School of Medicine
Washington D.C., District of Columbia
Gary Richmond, MD, PA
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
University of Miami
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Triple O Research Institute
West Palm Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
University of Maryland, Institute of Human Virology
Baltimore, Maryland
Henry Ford Health Systems
Detroit, Michigan
St. John Hospital and Medical Center
Southfield, Michigan
ACRIA
New York, New York
Montefiore Medical Center
The Bronx, New York
Carolinas HealthCare System
Charlotte, North Carolina
North Texas Infectious Disease Consultants
Dallas, Texas
Research Access Network
Houston, Texas
Clinical Research PR, Inc
San Juan, Puerto Rico
E-Da Hospital
Kaohsiung City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.